{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038044","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.806128+00:00","generated_at":"2026-06-09T14:15:05.945354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Q3 preliminary net product sales $5.0-5.2M; loss from ops down >80% YoY","bullets":["Phexxi net product sales expected $5.0-5.2M for Q3 2023; on track for third consecutive year of growth.","Selling/marketing expenses >75% lower, total operating expenses >65% lower versus Q3 2022.","Loss from operations reduced >80% YoY; expects lowest quarterly operating loss to date.","Fourth amendment to convertible notes: may repurchase $25M notes for as little as $14M; initial $1M paid.","Generic competitor amended ANDA; will not seek FDA approval until Phexxi patents expire in 2033."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038044","json":"https://secwatch.observer/filing/0001493152-23-038044.json","markdown":"https://secwatch.observer/filing/0001493152-23-038044.md","text":"https://secwatch.observer/filing/0001493152-23-038044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/0001493152-23-038044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:15:05.945354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e2b67b752f5ad5084f6fb249162f31791f2ecab","claim":"Evofem Biosciences, Inc. reported the third quarter of 2023 results: revenue $5.0 to $5.2 million.","evidence_excerpt":"gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives. ● Phexxi net product sales expected to be $5.0 to $5.2 million for the third quarter of 2023. ● Evofem remains on track to deliver its third consecutive year of net product sales growth. ● Selling and marketing expenses were","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/0001493152-23-038044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$5.0 to $5.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}